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The Covid-19 pandemic has caused significant morbidity and mortality among patients with
cancer. Most countries employed measures to prevent spread of Covid-19 infection which
include shielding, quarantine, lockdown, travel restrictions, physical distancing and the use of
personal protective equipment. This study was carried out to assess the change in patient
attendance and the efficacy of newly implemented strategies to mitigate the impact of Covid-
19 on services at the Lanka Hospital Blood Cancer Centre (LHBCC) in Colombo, Sri Lanka.
Methodology
Telephone consultation, infection control, personal protective measures and emergency
admission policy were implemented with the aim of having a Covid-19 free ward and to pre-
vent cross-infections. This descriptive cross-sectional study was conducted with 1399
patient episodes (in-patient care or day-case review). We analysed patients treated as in-
patient as well as day-case basis between 01st April 2020 and 31st December 2020.
Results
There were 977 day-case based episodes and 422 in-patient based episodes. There was a
14% drop in episode numbers compared to same period in 2019. There was no cross infec-
tion and no patients with Covid-19 related symptoms or positive test results entered the
LHBCC during the study period.
Conclusion
Services in blood cancer care were maintained to prevent late stage presentation and
adverse outcome. Measures implemented to prevent Covid-19 were effective to allow
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continuation of treatment. This study highlights the importance of implementing strict proto-
cols, clinical screening, use of appropriate personal protective equipment in delivering blood
cancer care during the Covid-19 pandemic. This is the only documented study relating to
outcome and successful applicability of measures to prevent spread of Covid-19 infection
and maintaining services among blood cancer patients in Sri Lanka.
Introduction
Haemato-Oncology patients have a higher risk of acquiring infections. It has been known for
decades that infection is the main cause of death in patients with blood cancer [1]. Due to com-
plexity of haematological malignancies, complications due to treatment, comorbidities associ-
ated with increasing age, these patients require multidisciplinary strategies and care from staff
experienced in blood cancer management.
Coronavirus disease 19 (Covid-19) is caused by Severe Acute Respiratory Syndrome
Corona Virus-2 (SARS-CoV-2) infection [2]. Three-phase approach in the bed site is proposed
in handling patients with Covid-19 infection [3]. It has dramatically changed global health
care deliveries, particularly cancer care. Covid-19 has an adverse effect on patient care in terms
of delay in diagnosis as well as treatment in addition to mortality associated with SARS-CoV-2
infection. Poor out come with persistence of virus in patients with haematological malignan-
cies is reported [4, 5]. Furthermore Covid-19 is shown to cause various haematological abnor-
malities [6]. This has brought new challenges to haematologists during the Covid-19 pandemic
[7] more so in the resource limited setting. Low-income countries are less prepared to face the
pandemic with fragile heath care systems hence rapid control measures are needed to prevent
catastrophic consequences [8].
SARS-CoV-2 is spread via direct or indirect contact via respiratory droplets, saliva, aerosols
or fomites [9] while crowded indoor environments are a particularly high-risk for transmis-
sion of infections [10]. World Health Organization (WHO) has made recommendations for
developing and implementing control measures to prevent transmission [11].
Sri Lanka is a developing country with diverse healthcare structure. Lanka Hospital Blood
Cancer Centre (LHBCC) is a dedicated unit established for the purpose of treating blood
related disorders in Colombo, Sri Lanka. Several new measures were implemented in April
2020 to reduce Covid-19 infection among patients and staff. The aim of the study was to ana-
lyze, the effect of Covid-19 pandemic on the patient numbers in LHBCC and the efficacy of
the implemented measures with regards to the outcome of Covid-19 prevention among the
patients and staff at the LHBCC.
Methodology
Ethical considerations
Study was considered as a quality improvement activity and approval was obtained from the
Lanka Hospitals medical research and the ethics committee for the collection and analysis of
anonymized data. Informed consent was obtained from all patients.
Site, subjects and implemented measures
This study was conducted at LHBCC. This is the first dedicated blood cancer centre in Sri
Lanka which consists of designated in-patient (8-bedded ward), day-case (4-bedded space)
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facility, staff and a strategy to treat blood cancers using treatment protocols from high-income
countries.
In-patients were not in contact directly or indirectly with patients who attending the day-
case facility. There were separate sets of nurses for in- and day- patients for each shift. In addi-
tion, LHBCC was used for training purposes of first Haemato-Oncology trainees from govern-
ment subsidised hospitals.
All patients treated as in-patient and day-case basis between 01st April 2020 to 31st Decem-
ber 2020 at the LHBCC were used in the study. We also collected similar data from all patients
treated as in-patient and day-case basis between 01st April 2019 to 31st December 2019 at
LHBCC for comparative purposes.
Following measures were implemented from 01.04.2020 to 31.12.2020.
1. Strict shielding / isolation advice was given to all patients with a diagnosis of blood cancer
on systemic chemotherapy or on supportive care.
2. All patients were actively monitored via telephone after discharge to lower patient atten-
dance without compromising care.
3. Colony stimulating factors (CSF) and oral antibacterial prophylaxis were used to minimize
patients coming in to the hospital with neutropenic sepsis.
4. A triage system was implemented to minimize cross-infections. All planned admissions
and day-case patients were reviewed via a telephone consultation on the day before and any
patient with fever, respiratory symptoms, recent travel to outbreak areas or those with a
contact history with positive patients were offered screening or delay non-essential
appointments.
5. A strict no visitor policy was implemented for day-cases while single by-stander policy was
in place for in-patients.
6. All emergency admissions were admitted to a dedicated separate section in the main hospi-
tal with an isolation facility.
7. Infection control training was provided to all clinical staff in addition to surgical / KN95
masks and eye protection measures.
8. All staff members were advised to measure their own body temperatures before work and
promptly report any symptoms of upper respiratory tract infection; any one with symptoms
suspicious of Covid-19 infection was screened with PCR testing.
9. Frequent disinfection of equipment and installation of protective shields were implemented
to maximise environmental control and to reduce droplet transmission.
Statistical analysis
Descriptive cross-sectional study was conducted with 1399 (422 in-patient and 977 day-case)
episode participants, using a non-probability convenience sampling method. We analysed
patients treated as in-patient and day-case basis between 01st April 2020 and 31st December
2020.
To obtain a thorough understanding of the sample of patients considered in the study, a
comprehensive descriptive analysis was conducted initially. Clinical and demographic charac-
teristics such as the type of the disease, neutrophil count, number of neutropenic episodes,
number of non-neutropenic episodes, in-patient episodes, day-case episodes, number
reviewed in-person and over the phone and according to disease type, age of the patient at
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presentation and gender were considered. Both numerical and graphical analyses were con-
ducted to conduct an in-depth analysis using R software. To statistically compare proportions
of various episodes like in-patient and day-case episodes that have occurred between 01st April
2020 and 31st December 2020 with the same period in the previous year, statistical hypothesis
tests for comparing two proportions were conducted. Further to this, proportions of occur-
rences of telephone and in-person reviews were also compared between the two periods. It was
also of interest to test various hypotheses related to percentage increase/decrease observed in
different types of episodes, total number of episodes, different types of reviews conducted and
total reviews conducted. To test these hypotheses statistical tests for testing one binomial pro-
portion were utilized.
The distribution of age of the whole sample and also when considered, the two groups sepa-
rately, is negatively skewed. Hence, median is used for analysis (S3 File).
For a two-tailed test of two proportions following null and alternative hypotheses were con-
sidered: H0: p1 = p2 versus H1: p1 6¼ p2, where p1 and p2 are the proportions of events in popu-
lations 1 and 2, respectively. In the case of a one-tailed test of two proportions following null
and alternative hypotheses were considered: H0: p1 = p2 versus H1: p1 > p2, where p1 and p2
are as defined above. Similarly, for a two-tailed test of a single proportion the following null
and alternative hypotheses were taken into consideration: H0: p = p0 versus H1: p 6¼ p0 where p
is the population proportion and p0 is the hypothesized value. For all tests 0.05 was taken as
the level of significance. All statistical hypothesis tests were conducted using R software.
Results
There were 1399 visits to the LHBCC. Forty seven percent were 60 years or over. Seventy per-
cent were reviewed on the day-case basis and forty three percent were females. Plasma cell dis-
orders (PCD), Lymphoproliferative disorders (LPD), Acute Myeloid Leukaemia (AML), Acute
Lymphoblastic Leukaemia (ALL), Myelodysplastic Syndrome (MDS) and other disorders
accounted for 33%, 27%, 11%, 3%, 11%, and 15% respectively.
The number of episodes reviewed in the LHBCC during the study period according to age,
gender disease type were as follows. A) Age� 60, In-patient (n = 185), Day-case (n = 553)
and< 60, In-patient (n = 237) and Day-case (n = 424); B) Gender male, In-patient (n = 242),
Day-case (n = 557) and female, In-patient (n = 180) and Day-case (n = 420); C) Disease type,
PCD, In-patient (n = 57), Day-case (n = 405); LPD, In-patient (n = 113), Day-case (n = 269);
AML, In-patient (n = 46), Day-case (n = 106); ALL, In-patient (n = 12), Day-case (n = 35);
MDS, In-patient (n = 70), Day-case (n = 81); Other, In-patient (n = 124), Day-case (n = 81).
There were 324 neutropenic episodes during the study period. Thirty percent of those epi-
sodes were treated as in-patient due to neutropenic sepsis.
Clinical and demographic characteristics of patients are summarized in Table 1 and Fig 1.
Thirty six percent (353) of day-case based reviews were done over the phone during the
study period. The percentage of PCD, LPD, AML, ALL, MDS and other disorders reviewed
were 15%, 59%, 53%, 8%, 70% and 20% respectively (Fig 2).
During the same period in 2019 we have treated a total of 1633; 574 as in-patient and 572
in-person in the day-case and 487 over telephone consultations. During the study period com-
pared to the same period in 2019, 14% decrement in total was observed with a 95% confidence
interval (CI) of (12.66%, 16.12%). Among these a statistically significant decrement (26% with
95% CI (22.91%, 30.30%) and p-value 0.002) was observed during the study period compared
to same period in 2019 with regards to in-patient episodes whereas he increment observed in
2020 compared to 2019 in day-case (8% with a 95% CI of (6.21%, 9.52%) and p-value 0.002)
was also found to be statistically significant under 0.05 significance level (Tables 2 and 3).
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Thirty six percent of day-case based episodes were reviewed over the phone in the study
period compared to 46% in the same period in 2019 (Fig 3). A decrement of day-case based
reviews in the study period compared to the same period in 2019 in total was observed as 8%
with a 95% CI of (6.21%, 9.52%). There was a statistically significant drop of 28% (with a 95%
CI of (23.59%, 31.71%) and p-value 0.000) in the telephone consultations but in-person
reviews were up by 9% (with a 95% CI of (6.86%, 11.75%) and this increment observed was
found to be statistically significant (p-value 0.000) (Tables 4 and 5).
24 patient tests performed as directed by LHBCC. There were no infections recorded in
patients who got admitted or were cared in the day-care setting or among the staff in the
LHBCC during the study period. A total of 5 staff with suspected Covid-19 symptoms or con-
tact history were isolated. However, none of them had a positive PCR result. Two patients
identified with suspected Covid-19 symptoms, tested positive on the out-patient basis admit-
ted to a separate ward with isolation facilities. Both were treated at quarantine centers outside
the main hospital before returning for follow up in LHBCC.
In addition, one out-sourced janitorial staff member had symptomatic Covid-19 diagnosed
during work and was treated at an isolation facility.
Discussion
Patients on systemic chemotherapy are at a higher risk of death with Covid-19 infection.
Higher mortality is reported in Haemato-Oncology patients compared to those with solid can-
cers [5, 12] which is higher than 1.4%, originally reported from China [2]. In addition, Covid-
19 caused devastating effect on cancer patients due to delayed diagnosis and treatment [13].
Implications of continuing treatment has to be weighed against the implications on outcome
due to treatment delay. There are published guideline about blood cancer care during Covid-
19 pandemic [14, 15]. Delay in diagnosis and treatment is likely to cause a spike in late stage
cancer presentation in the future.
Sri Lanka is a developing country with a diverse health care system. Unlike high-income
countries, hospitals in Sri Lanka are likely to have different approaches in managing the same
disease and also significant heterogeneity exists with regard to diagnostic and treatment facili-
ties, access to trained personnel and supportive care. LHBCC was established in collaboration
with colleagues from government subsidised hospitals. We have previously published data on
the successful application of British treatment protocols in acute myeloid leukaemia [16], in
Table 1. Clinical and demographic characteristics of total episodes (n = 1399) reviewed during the study period.
In-patient care Day-case p-value
Total episodes 422 977 0.000
Gender (male/female) 242 / 180 557 / 420 0.681
Median Age (IQR) 59 (31.25) 61 (23.5) 0.0001
Disease Type
Plasma Cell Disorders 57 405 0.000
LPD 113 269 0.794
AML 46 106 1.000
ALL 12 35 0.523
MDS 70 81 0.000
Other 124 81 0.000
Neutropenic episodes 98 226 1.000
Covid-19 PCR performed 26
Telephone Consultations 353
https://doi.org/10.1371/journal.pone.0256941.t001
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Hodgkin Lymphoma [17] and other haematological malignancies (manuscript in prepara-
tion). Covid-19 incidence is on the rise in Sri Lanka [18]. LHBCC also suffered the impact of
Covid-19 outbreak and had a challenge to balance the risk and benefit of continuing treatment
and keeping the centre free of this infection.
We had to make the difficult decision of treating aggressive diseases while at the same time
minimizing the risk of exposure to Covid-19 and avoiding medication related toxicity with limited
resources. We redesigned the LHBCC and introduced stringent precautions against viral trans-
mission which also included hygienic behavior outside the work place for staff and patients.
Our study showed 14% drop in episodes after Covid-19 epidemic compared to pre-Covid
-19 era. Delay in treatment of patients with aggressive haematological malignancies can cause
Fig 1. Patients reviewed as in-patient and as day-case according to A) age, B) gender, C) disease type and D) neutrophil count.
https://doi.org/10.1371/journal.pone.0256941.g001
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detrimental effects on the outcome [19]. In addition, as published previously it is likely that
Covid-19 pandemic will have an impact on the morbidity and mortality in cancer patients in
the future [13]. Willan et al, reported 53% less diagnosis due to reduction in patient numbers
and doctors performing less procedures [7]. Maintaining 86% episodes in LHBCC was consid-
ered as an important step in preventing inferior out come and late relapses due to sub optimal
Fig 2. Patients reviewed on day-case basis in person (n = 624) and telephone review (n = 353) during the study period according to disease
type.
https://doi.org/10.1371/journal.pone.0256941.g002
Table 2. In-patient, day- case based and total episodes in 2020 compared to 2019.
2019 count Proportion 2020 count Proportion % decrement/increment (95% CI)
In-patient 574 0.35 422 0.30 26% (22.91%, 30.30%)
Day-case 1059 0.65 977 0.70 8% (6.21%, 9.52%)
Total Episodes 1633 1399 14% (12.66%, 16.12%)
https://doi.org/10.1371/journal.pone.0256941.t002
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treatment in the future. There was a higher drop in in-patient episodes but increase in the pro-
portion of episodes in the day-case. This may be related to drop in total patient numbers, less
admissions due to better day-case, telephone advice or better preventive measures against
complications related to treatment. A larger study may be needed to investigate it further.
Although we cannot generalize our conclusions about the cancer care to the rest of the
country.
Covid-19 can spread from contaminated surfaces, respiratory droplets or other body fluids
via respiratory or non-respiratory surfaces [20, 21]. Requesting patients to be at their homes to
avoid viral transmission was highly effective. Behavior modification can reduce the transmis-
sion, prevent disease spread and contribute to release the overwhelmed health care system
[22]. Telephone screening has been shown to be effective in cancer care as reported previously
[23–25]. We have had an active telephone consultation facility since 2013. Thirty six percent of
LHBCC day-case consultations were done via telephone during the study period. However,
forty five percent of consultations were carried out using the telephone facility during the
same period in 2019. This data shows that we had an established effective telephone
Table 3. Proportional comparison of in-patient, day- case based and total episodes in 2020 compared to 2019.
Proportion comparison between 2019 and
2020 p-value
Conclusion % decrement/ Increment
Significance p-value
Conclusion
In-patient 0.003 significant difference 0.441 %decrement is not significantly
different from 25%0.002 Significantly lower in
2020
Day-case 0.004 significant difference 0.778 %increment is not significantly




0.721 %decrement is not significantly
different from 14%
https://doi.org/10.1371/journal.pone.0256941.t003
Fig 3. A). Patient episodes reviewed on in-patient and day-case basis in 2020 compared to in-patient and day-case basis in 2019. B) Day-case episodes reviewed in-
person and on the telephone in 2020 compared to in-person and telephone review in 2019.
https://doi.org/10.1371/journal.pone.0256941.g003
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consultation strategy before Covid-19 pandemic to prevent infections among blood cancer
patients. Keeping high risk patients at home was a very effective and may be the most effective
strategy in keeping patients safe. Furthermore, we utilized measures with proven benefit such
as primary prophylaxis with CSF [26] and oral antibacterial medications to minimize patients
coming in to the hospital with neutropenic sepsis. There were 324 episodes with neutropenia
and 30% of those ended up with neutropenic sepsis but with no mortality.
We implemented an additional telephone consultation service for risk assessment with
every scheduled admission for in-patient care or for day-case treatment to keep LHBCC a
Covid-19-free area. Telephone triage before attending to medical clinic has been shown to be
effective in managing patients during the Covid-19 pandemic [27]. Two positive PCR reports
were noted on patients; one patient identified with suspected Covid-19 symptoms, tested on
the outpatient basis and another with similar symptoms admitted to a different ward with iso-
lation facilities. No patient with Covid-19 related symptoms or positive results entered
LHBCC making this a highly effective strategy.
Health professionals are more vulnerable to Covid-19 and also can pass it on to other
patients due to the nature of their profession [28]. It is of paramount importance to protect
them from clinical or sub-clinical infections [29]. Using face shields/goggles, regular decon-
tamination of the patient’s surroundings, use of N95 and use of single use surgical gowns have
been shown to protect separate staff from contacting Covid-19 [30]. One of our out-sourced
janitorial staff members had symptomatic Covid-19 but neither staff nor patients contacted
virus from this member. We believe our data reflects the efficacy of stringent measures we
employed to prevent cross infections in the ward. The threat of infection among patients and
staff had to be taken seriously if we were to continue safe practice in the LHBCC. Several stud-
ies have shown the difference in morbidity and mortality according to availability of nursing
and medical staff [31, 32]. Our center has a resident full-time consultant hematologist and dur-
ing the time of the epidemic we restructured the LHBCC to maintain a higher patient nurse
ratio. We believe this to be one of the key elements in delivery of a safe, secure and less stressful
practice.
Routine screening and PCR / RAT testing have been shown to reduce infection rate [33,
34]. However, we did not routinely check patients for SARS-CoV-2 by PCR and this was
Table 4. Day-cases based episodes reviewed over the phone during the study period compared to 2019.
2019 count Proportion out of total 2020 count Proportion out of total % decrement/Increment (95% CI)
Telephone review 487 0.46 353 0.36 28% (23.59%, 31.71%)
In person review 572 0.54 624 0.64 9% (6.86%, 11.75%)
Total 1059 977 8% (6.21%, 9.52%)
https://doi.org/10.1371/journal.pone.0256941.t004
Table 5. Proportional comparison of day-cases based episodes reviewed over the phone during the study period compared to 2019.
Proportion comparison between 2019 and
2020 p-value





0.000 significant difference 0.209 %decrement is not significantly




0.000 significant difference 0.487 %increment is not significantly
different from 10%0.000 Significantly higher in
2020
Total 0.778 %decrement is not significantly
different from 8%
https://doi.org/10.1371/journal.pone.0256941.t005
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reserved for high risk patients mainly due to financial and practical reasons. However, we real-
ise this may be a requirement if the future if infection rate continues to rise or if there is an out-
break in LHBCC. We have included RAT testing in the proposed advanced admission and
outpatient care policy in LHBCC (S4 File).
We had a very successful control of Covid-19 infection at LHBCC and we believe the suc-
cess was due to stringent precautionary measures adapted at the LHBCC. Others have reported
similar data from the developed world following strict preventative measures [19]. The mea-
sures implemented to prevent Covid-19 were effective to allow continuing treatment. How-
ever, it is not possible to differentiate or assess the efficacy of implemented individual
measures.
We did not delay in commencing intended treatment due to Covid-19 pandemic and this
study demonstrates that blood cancer patients can be managed safely even in a resource lim-
ited setting using high clinical awareness, education, telephone screening and performing PCR
on symptomatic patients. Urgent chemotherapy should not be delayed and our data suggests
patients and staff can be kept Covid-19 free despite continuing on aggressive treatment and
having limited resources. The success we encountered may reflect staff and patient awareness
and commitment. Clear guidelines, improved communication and strong leadership are nec-
essary to protect patients and staff from Covid-19 infection.
Limitations
We recognise limitations in this study. This study was a single-centre study and further studies
are necessary with a large multi-centre samples before reaching definitive conclusions. There
are certain disadvantages particularly related to financial implications related to increase cost
of treatment and drop in income due to smaller number of patients and psychological impact
of Covid-19 and implemented measures on healthcare workers and patients. In addition, the
results might not be generalized due to differences socioeconomic backgrounds in other cen-
tres. Larger studies may be necessary to address above limitations.
Conclusion
Services in blood cancer care were maintained to prevent late stage presentation and adverse
outcome. However there was a significant drop in number of patients attending blood cancer
care during the Covid-19 pandemic. Measures implemented to prevent Covid-19 were effec-
tive to allow continuation of treatment. This study highlights the importance of implementing
strict protocols, clinical screening, use of appropriate personal protective equipment in deliver-
ing blood cancer care during the Covid-19 pandemic. This is the only documented study relat-
ing to outcome and successful applicability of measures to prevent spread of Covid-19
infection and maintaining services among blood cancer patients in Sri Lankan.
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